| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.3 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |